# SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma

> **NCT04014101** · PHASE2 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** SHR-1210
- **DRUG:** apatinib

## Key facts

- **NCT ID:** NCT04014101
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-01
- **Primary completion:** 2019-10-01
- **Final completion:** 2020-10-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2019-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04014101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04014101, "SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04014101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*